Alan H. Bryce, MD

Alan H. Bryce, MD, is the chief clinical officer, a professor in the Department of Molecular Medicine at the Translational Genomics Research Institute, and an oncologist at City of Hope Cancer Center Phoenix.

Articles by Alan H. Bryce, MD

Dr. Alan Bryce on Molecular Testing in Metastatic or High-Risk Stage III Melanoma

ByAlan H. Bryce, MD

May 8th 2015

Alan H. Bryce, MD, medical oncologist, Mayo Clinic, discusses the need for molecular testing in patients with metastatic or high-risk stage III melanoma.

Alan H. Bryce, MD

Articles by Alan H. Bryce, MD

Dr. Alan Bryce on Molecular Testing in Metastatic or High-Risk Stage III Melanoma

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies